M Shima
Overview
Explore the profile of M Shima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
262
Citations
1733
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Minami H, Nogami K, Yada K, Ogiwara K, Furukawa S, Soeda T, et al.
J Thromb Haemost
. 2018 Nov;
17(1):126-137.
PMID: 30444568
Essentials Emicizumab mimics factor (F)VIIIa cofactor function, augments the intrinsic tenase activity. We assessed the emicizumab-driven hemostatic function in FXI-deficient plasmas. Emicizumab improved the coagulation potentials in severe FXI-deficient plasma....
2.
Adcock D, Strandberg K, Shima M, Marlar R
Int J Lab Hematol
. 2018 Jul;
40(6):621-629.
PMID: 29979821
Haemophilia A and B diagnosis and disease severity classification are determined on the basis of results from factor VIII (FVIII) and factor FIX (FIX) activity assays, respectively. These assays are...
3.
Nogami K, Taki M, Matsushita T, Ohga S, Oka T, Horikoshi Y, et al.
Haemophilia
. 2018 Jun;
24(5):e328-e337.
PMID: 29902361
Introduction: Immune tolerance induction (ITI) was the primary therapeutic approach to eradicate inhibitors in haemophilia patients. Several large ITI registries had been reported, but successful predictors of ITI outcome are...
4.
Dunkley S, Lam J, John M, Wong R, Tran H, Yang R, et al.
Haemophilia
. 2018 Jun;
24(4):e243-e244.
PMID: 29901827
No abstract available.
5.
Nogami K, Soeda T, Matsumoto T, Kawabe Y, Kitazawa T, Shima M
J Thromb Haemost
. 2018 May;
16(7):1383-1390.
PMID: 29734520
Summary: Background Emicizumab is an anti-factor (F)IXa/X bispecific monoclonal antibody (mAb), mimicking the factor (F)VIIIa cofactor activity. Emicizumab does not require activation by thrombin and its shortening effect on the...
6.
Nogami K, Matsumoto T, Tabuchi Y, Soeda T, Arai N, Kitazawa T, et al.
J Thromb Haemost
. 2018 Apr;
16(6):1078-1088.
PMID: 29645406
Summary: Background Emicizumab is an anti-activated factor IX/FX bispecific antibody that mimics activated FVIII cofactor function. Emicizumab does not require activation by thrombin, and its effect on shortening the activated...
7.
Dunkley S, Lam J, John M, Wong R, Tran H, Yang R, et al.
Haemophilia
. 2018 Feb;
24(3):366-375.
PMID: 29465806
Optimal haemophilia care is best established and implemented through a well-coordinated plan guided by clearly defined principles and priorities. A document which enunciates those details is therefore important. A successful...
8.
Young G, Ezban M, Clausen W, Negrier C, Oldenburg J, Shima M
Haemophilia
. 2017 Sep;
23(6):e528-e530.
PMID: 28922522
No abstract available.
9.
Furukawa S, Nogami K, Ogiwara K, Yada K, Shima M
Haemophilia
. 2017 Aug;
23(5):e481-e484.
PMID: 28771891
No abstract available.
10.
Matsumoto T, Nogami K, Tabuchi Y, Yada K, Ogiwara K, Kurono H, et al.
Haemophilia
. 2017 Jul;
23(5):e427-e435.
PMID: 28750470
Introduction: A recently developed method to assess comprehensive coagulation function, clot waveform analysis (CWA), accurately detect low levels (<1 IU/dL) of factor VIII activity (FVIII:C) in haemophilia A patients (HA-pts)....